SIGA Technologies
SIGASIGA Technologies is a commercial-stage pharmaceutical company focused on health security and medical countermeasures for biological threats.
Earnings
Next report
Nov 5, 2026 (in 2 months)Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
SIGA Technologies is a commercial-stage pharmaceutical company focused on health security and medical countermeasures for biological threats. The company specializes in the development and commercialization of antiviral solutions for orthopoxviruses, primarily serving as a strategic provider to the U.S. and international governments. Its core value proposition lies in providing essential treatments for high-consequence pathogens like smallpox and other related viral diseases.
SIGA is a leading provider of the only FDA-approved smallpox antiviral, maintaining a significant long-term relationship with the U.S. Strategic National Stockpile.
FAQ
- What is SIGA Technologies's market cap?
- SIGA Technologies (SIGA) has a market capitalization of $214.1M and trades on NASDAQ.
- What is SIGA Technologies's revenue and profitability?
- SIGA Technologies generated $53.7M in trailing twelve-month revenue with net income of $38.1M, representing a net margin of 43.2%. Gross margin stands at 54.4%, with free cash flow of $76.6M. The latest reported period is Q2 2026.
- Who are SIGA Technologies's competitors?
- SIGA Technologies's key competitors include Emergent BioSolutions Inc., Spero Therapeutics, Inc. Common Stock, Karyopharm Therapeutics Inc., and others. These companies compete in similar markets and product categories.
- Who does SIGA Technologies partner with?
- SIGA Technologies's notable partners include Meridian Medical Technologies, W.R. Grace and Company, Catalent Pharma Solutions LLC, and others.
- Where is SIGA Technologies headquartered?
- SIGA Technologies is headquartered in United States of America and employs approximately 45 people. It has been publicly traded since 1997.
